[
    {
        "file_name": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement.txt",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "The timeline for conducting the Clinical Trials is attached as Exhibit I hereto (the \"Timeline\"). In conducting the Clinical Trials, the Parties will use Commercially Reasonable Efforts to complete each activity specified on the Timeline (each, a \"Clinical Trial Activity\") by the date specified for such Clinical Trial Activity on the Timeline. The Parties will notify the JDC in writing upon completion or achievement of each of their designated Clinical Trial Activities.",
                "changed_text": "The timeline for conducting the Clinical Trials is attached as Exhibit I hereto (the \"Development Schedule\"). In conducting the Clinical Trials, the Parties will use all efforts to complete each activity specified on the Development Schedule (each, a \"Development Milestone\") by the date specified for such Development Milestone on the Development Schedule. The Parties will notify the JDC in writing upon completion or achievement of each of their designated Development Milestones.",
                "explanation": "The terms 'Timeline' and 'Clinical Trial Activity' are replaced by 'Development Schedule' and 'Development Milestone,' respectively, and 'Commercially Reasonable Efforts' is replaced with 'all efforts,' thus creating confusion over what efforts are required of each party.",
                "location": "2.3.1"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "Each Party will conduct the Phase 3 Trial within its Territory, and SFJ will conduct each other Clinical Trial in the SFJ Territory, and perform all other responsibilities assigned to it hereunder in connection with any such Clinical Trial in compliance with the applicable Protocol, all Applicable Laws and the terms hereof.",
                "changed_text": "Each Party will conduct the Phase 3 Trial within its Territory, and SFJ will conduct each other Research Program in the SFJ Territory, and perform all other responsibilities assigned to it hereunder in connection with any such Research Program in compliance with the applicable Plan, all Applicable Laws and the terms hereof.",
                "explanation": "The terms 'Clinical Trial' and 'Protocol' are replaced with 'Research Program' and 'Plan,' respectively. It's unclear whether the parties need to follow all applicable clinical trial requirements (GCP) if the Clinical Trials are now called Research Programs.",
                "location": "2.2.2"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "Promptly following the Effective Date during the Development Term, PB will identify one (1) individual with knowledge of the Phase 3 Trial Protocol and the Product who will be made available at reasonable times during normal business hours in such employee's country of residence upon reasonable advance notice to answer SFJ's questions directly pertaining to such Protocol.",
                "changed_text": "Promptly following the Effective Date during the Development Term, PB will identify one (1) individual with knowledge of the Phase 3 Trial Design and the Product who will be made available at reasonable times during normal business hours in such employee's country of residence upon reasonable advance notice to answer SFJ's questions directly pertaining to such Design.",
                "explanation": "The term 'Phase 3 Trial Protocol' is replaced with 'Phase 3 Trial Design.' This introduces confusion as to whether this individual is familiar with the regulatory requirements in the Protocol or simply the trial's broad design.",
                "location": "2.5.2"
            }
        ]
    }
]